KRAS2 Antibody (C-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P01116 |
---|---|
Clone Names | 71213131 |
Gene ID | 3845 |
---|---|
Other Names | GTPase KRas, K-Ras 2, Ki-Ras, c-K-ras, c-Ki-ras, GTPase KRas, N-terminally processed, KRAS, KRAS2, RASK2 |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | KRAS |
---|---|
Synonyms | KRAS2, RASK2 |
Function | Ras proteins bind GDP/GTP and possess intrinsic GTPase activity (PubMed:20949621). Plays an important role in the regulation of cell proliferation (PubMed:23698361, PubMed:22711838). Plays a role in promoting oncogenic events by inducing transcriptional silencing of tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a ZNF304-dependent manner (PubMed:24623306). |
Cellular Location | Cell membrane; Lipid-anchor; Cytoplasmic side. Endomembrane system. Cytoplasm, cytosol |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This gene, a Kirsten ras oncogene homolog from themammalian ras gene family, encodes a protein that is a member ofthe small GTPase superfamily. A single amino acid substitution isresponsible for an activating mutation. The transforming proteinthat results is implicated in various malignancies, including lungadenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreasand colorectal carcinoma. Alternative splicing leads to variantsencoding two isoforms that differ in the C-terminal region.
References
Bruckman, K.C., et al. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 110(5):632-637(2010)Wong, K.K., et al. Am. J. Pathol. 177(4):1611-1617(2010)Irahara, N., et al. Diagn. Mol. Pathol. 19(3):157-163(2010)Carotenuto, P., et al. Pharmacogenomics 11(8):1169-1179(2010)Leventopoulos, G., et al. Clin. Exp. Rheumatol. 28(4):556-557(2010)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.